Citius Pharmaceuticals In... (CTXR)
| Bid | 1.17 |
| Market Cap | 10.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -5.82 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | 1.16 |
| Analyst | Buy |
| Ask | 1.23 |
| Volume | 247,233 |
| Avg. Volume (20D) | 292,453 |
| Open | 1.21 |
| Previous Close | 1.20 |
| Day's Range | 1.15 - 1.22 |
| 52-Week Range | 1.15 - 26.25 |
| Beta | 1.18 |
About CTXR
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected c...
Analyst Forecast
According to 4 analyst ratings, the average rating for CTXR stock is "Buy." The 12-month stock price forecast is $54.5, which is an increase of 4518.64% from the latest price.
Stock Forecasts
8 months ago · newsfilecorp.com
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma ...
8 months ago · newsfilecorp.com
Biopharma Stocks Transformative Innovation for the Future of HealthVancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innov...
